A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients With Advanced Solid Tumors

Trial Profile

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients With Advanced Solid Tumors

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 Feb 2018

At a glance

  • Drugs BA 3011 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors BioAtla
  • Most Recent Events

    • 06 Feb 2018 Status changed from planning to not yet recruiting.
    • 25 Jan 2018 New trial record
    • 24 Jan 2018 According to a Bioatla media release, the U.S. Food and Drug Administration (FDA) has cleared BioAtla's Investigational New Drug application (IND) for BA3011.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top